 Neprilysin
"Neprilysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
| Descriptor ID |
D015260
|
| MeSH Number(s) |
D08.811.277.656.300.480.600 D08.811.277.656.675.374.600 D23.050.285.550 D23.101.140.500
|
| Concept/Terms |
Neprilysin- Neprilysin
- CALLA Antigen
- Enkephalinase
- Enkephalinase-24.11
- Enkephalinase 24.11
- Kidney-Brush-Border Neutral Proteinase
- Kidney Brush Border Neutral Proteinase
- Neutral Proteinase, Kidney-Brush-Border
- Membrane Metallo-Endopeptidase
- Membrane Metallo Endopeptidase
- Metallo-Endopeptidase, Membrane
- Neutral Endopeptidase
- Endopeptidase, Neutral
- Neutral Endopeptidase 24.11
- Endopeptidase 24.11, Neutral
- Thermolysin-Like Metalloendopeptidase
- Metalloendopeptidase, Thermolysin-Like
- Thermolysin Like Metalloendopeptidase
- YGG-Forming Enzyme
- Enzyme, YGG-Forming
- YGG Forming Enzyme
- Common Acute Lymphoblastic Leukemia Antigens
- Antigens, Leukemia, Common Acute Lymphoblastic
- Atriopeptidase
- CD10 Antigen
- Antigen, CD10
- Antigens, CD10
- CD10 Antigens
- Endopeptidase-24.11
- Endopeptidase 24.11
- Enkephalin Dipeptidyl Carboxypeptidase
- Carboxypeptidase, Enkephalin Dipeptidyl
- Dipeptidyl Carboxypeptidase, Enkephalin
|
Below are MeSH descriptors whose meaning is more general than "Neprilysin".
Below are MeSH descriptors whose meaning is more specific than "Neprilysin".
This graph shows the total number of publications written about "Neprilysin" by people in this website by year, and whether "Neprilysin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 2001 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neprilysin" by people in Profiles.
-
Diamond J, Ayodele I, Fonarow GC, Joynt-Maddox KE, Yeh RW, Hammond G, Allen LA, Greene SJ, Chiswell K, DeVore AD, Yancy C, Wadhera RK. Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults: Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023 06 01; 8(6):545-553.
-
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021 08 17; 10(16):e021459.
-
Dickert NW, Mitchell AR, Venechuk GE, Matlock DD, Moore MA, Morris AA, Pierce KJ, Speight CD, Allen LA. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost. Circ Cardiovasc Qual Outcomes. 2020 12; 13(12):e007070.
-
Venechuk GE, Allen LA, Doermann Byrd K, Dickert N, Matlock DD. Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circ Cardiovasc Qual Outcomes. 2020 09; 13(9):e006255.
-
Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, Heidenreich PA, Laskey WK, Yancy CW, Greiner MA, Hardy NC, Kavati A, Park S, Mentz RJ, Fonarow GC, O'Brien EC. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiol. 2020 03 01; 5(3):292-299.
-
O'Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Grzeslo A, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk LM, Moe GW, Swiggum E, Toma M, Virani SA, Zieroth S, De S, Matteau S, Parent MC, Asgar AW, Cohen G, Fine N, Davis M, Verma S, Cherney D, Abrams H, Al-Hesayen A, Cohen-Solal A, D'Astous M, Delgado DH, Desplantie O, Estrella-Holder E, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Lee D, Masoudi FA, McKelvie RS, Rajda M, Ross HJ, Sussex B. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020 02; 36(2):159-169.
-
Luo N, Lippmann SJ, Mentz RJ, Greiner MA, Hammill BG, Hardy NC, Laskey WK, Heidenreich PA, Chang CL, Hernandez AF, Curtis LH, Peterson PN, Fonarow GC, O'Brien EC. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. J Am Heart Assoc. 2019 02 05; 8(3):e010484.
-
Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
-
Buttrick P. Neprilysin Inhibition: What We Know and What We Don't Know. J Card Fail. 2018 04; 24(4):276-277.
-
Luo N, Ballew NG, O'Brien EC, Greiner MA, Peterson PN, Hammill BG, Hardy NC, Laskey WK, Heidenreich PA, Chang CL, Hernandez AF, Curtis LH, Mentz RJ, Fonarow GC. Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. Am Heart J. 2018 06; 200:134-140.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|